Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study-Reference-Cited by-同舟云学术

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Published:2021-09 Issue:9 Volume:22 Page:1312-1321
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gaspar Nathalie,Venkatramani Rajkumar,Hecker-Nolting Stefanie,Melcon Soledad Gallego,Locatelli Franco,Bautista Francisco,Longhi Alessandra,Lervat Cyril,Entz-Werle Natacha,Casanova Michela,Aerts Isabelle,Strauss Sandra J,Thebaud Estelle,Morland Bruce,Nieto Adela Cañete,Marec-Berard Perrine,Gambart Marion,Rossig Claudia,Okpara Chinyere E,He Cixin,Dutta Lea,Campbell-Hewson Quentin

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Progress in the chemotherapeutic treatment of osteosarcoma;Zhang;Oncol Lett,2018

2. Phase-II trials in osteosarcoma recurrences: a systematic review of past experience;Omer;Eur J Cancer,2017

3. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients;Bielack;J Clin Oncol,2009

4. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2018

5. Anti-angiogenesis target therapy for advanced osteosarcoma (Review);Xie;Oncol Rep,2017

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Targeted anti-angiogenesis therapy for advanced osteosarcoma;Frontiers in Oncology;2024-08-26

3. Genetic and molecular profiling in bone sarcomas: advancing personalized treatment approaches;InterConf;2024-08-19

4. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

5. The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma;BMC Cancer;2024-08-01